Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.35 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966472 | 0.86 | GLA (0.40) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL9555439 | 0.86 | MAPT (0.35) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL11409353 | 0.79 | ADORA3 (0.45) | MAPTLMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7088421 | 0.77 | KDM1A (0.36) | MAPTLMNAALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL30052413 | 0.74 | TRPA1 (0.35) | MAPTLMNAALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL5565774 | 0.74 | KDM1A (0.33) | MAPTLMNAKDM1ARAB9ANFKB1 | |
| SCHEMBL27919393 | 0.74 | MAPT (0.37) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL29962540 | 0.73 | KDM1A (0.42) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL30874319 | 0.73 | KDM1A (0.38) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL28413151 | 0.73 | KDM1A (0.42) | MAPTLMNAHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748988-A1 | A PROCESS FOR THE PREPARATION OF IMINOSTILBENE DERIVATIVES | Milanese, Alberto (IT) | 2007-02-07 | — | — | EP | claimed |
| WO-2005118550-A1 | A PROCESS FOR THE PREPARATION OF IMINOSTILBENE DERIVATIVES | MILANESE ALBERTO (IT) | 2005-12-15 | — | — | WO | claimed |
| WO-2008108639-A1 | CO-CRYSTALLINE FORMS OF CARBAMAZEPINE | AVANTIUM HOLDING B.V. (NL) | 2008-09-12 | — | — | WO | disclosed |
| US-20060094709-A1 | Methods for the treatment of bipolar disorder using carbamazepine | VALIDUS PHARMACEUTICALS LLC | 2006-05-04 | — | — | US | disclosed |
| US-6977253-B2 | Methods for the treatment of bipolar disorder using carbamazepine | SHIRE PHARMACEUTICAL DEVELOPMENT INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050124601-A1 | in extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | VALIDUS PHARMACEUTICALS LLC | 2005-06-09 | — | — | US | disclosed |
| EP-1026158-B1 | Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine | MAX INDIA LTD (IN) | 2003-09-24 | — | — | EP | disclosed |
| US-6245908-B1 | Process for preparing carbamazepine from iminostilbene | MAX INDIA LIMITED (IN) | 2001-06-12 | — | — | US | disclosed |
| EP-1026158-A1 | Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine | Max India Limited (IN) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094709-A1 | Methods for the treatment of bipolar disorder using carbamazepine | GABBR2, GABRE, GABBR1 | MAPT 549/4885LMNA 1915/4885HDAC3 64/4885 |
| US-20050124601-A1 | in extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | SLC6A1, SLC6A11, GABRE | MAPT 515/4885LMNA 913/4885HDAC3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.